| Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment G Koçkaya, A Wertheimer Journal of pharmacy practice 24 (3), 345-350, 2011 | 25 | 2011 |
| An overview of the orphan medicines market in Turkey G Koçkaya, AI Wertheimer, P Kilic, P Tanyeri, IM Vural, A Akbulat, ... Value in Health Regional Issues 4, 47-52, 2014 | 20 | 2014 |
| Türkiye özel ve kamu sağlik sigortaciliği prim/hasarsağlik harcamasi değerlendirmesi G Koçkaya, K Atikeler, F YENİLMEZ Sosyal Güvence, 82-101, 2016 | 19 | 2016 |
| Analysis of patient access to orphan drugs in Turkey G Koçkaya, S Atalay, G Oğuzhan, M Kurnaz, S Ökçün, Ç Sar Gedik, ... Orphanet journal of rare diseases 16, 1-8, 2021 | 16 | 2021 |
| Impact of health policy changes on trends in the pharmaceutical market in Turkey ES Yılmaz, G Koçkaya, FB Yenilmez, M Saylan, M Tatar, A Akbulat, ... Value in Health Regional Issues 10, 48-52, 2016 | 14 | 2016 |
| What are the top most costly diseases for USA? The alignment of burden of illness with prevention and screening expenditures G Kockaya, A Wertheimer Health 2 (10), 1174-1178, 2010 | 14 | 2010 |
| Pharmaceutical market access in developed markets G Koçkaya, A Wertheimer SEEd, 2018 | 13 | 2018 |
| Orphan drug regulations in Turkey P Kılıç, G Koçkaya, Ö Yemşen, C Tan, FH Öztunca, P Aksungur, S Kerman Journal of Pharmaceutical Health Services Research 4 (3), 151-153, 2013 | 11 | 2013 |
| Off-label and unlicensed oncology medicine use in Turkey: a retrospective analysis of computer records of the Turkish Ministry of Health G Koçkaya, M Polat, İM Vural, A Akbulat, BD Dedeoglu, H Akar, S Kerman Journal of Pharmaceutical Health Services Research 2 (1), 53-57, 2011 | 11 | 2011 |
| Pharmaceutical market access in emerging markets G Koçkaya, A Wertheimer SEEd, 2016 | 10 | 2016 |
| Cost effectiveness and economic value of obesity surgery for Turkey (CEVOS-T) G Koçkaya, FB Yenilmez, G Ergin, K Atikeler, M Tatar Obesity Medicine 1, 33-37, 2016 | 8 | 2016 |
| Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey G Kockaya, A Kose, FB Yenilmez, O Ozdemir, E Kucuksayrac Cost Effectiveness and Resource Allocation 13, 1-10, 2015 | 8 | 2015 |
| An estimation of the effect of 100% Compliance with Diabetes Treatment: Can we reduce cost of illness with higher compliance rates? G Kockaya, AI Wertheimer INNOVATIONS in pharmacy 2 (2), 2011 | 8 | 2011 |
| PIN56 cost of COVID-19 patients treatment in Turkey EB Karahan, S Öztopçu, M Kurnaz, S Ökçün, Z Caliskan, G Oğuzhan, ... Value in Health 23, S554, 2020 | 7 | 2020 |
| Sosyoekonomik durumun diyabet ile ilişkisi ve diyabete etkisinin incelenmesi G OGUZHAN, E DÜNDER, S ÖKÇÜN, G KOÇKAYA Türkiye Diyabet ve Obezite Dergisi 4 (2), 71-78, 2020 | 7 | 2020 |
| Analysis of the treatment cost of HIV/AIDS in Turkey G Kockaya, TE Zengin, FB Yenilmez, C Dalgic, SMS Malhan, P Cerci, ... Farmeconomia. Health economics and therapeutic pathways 17 (1), 13-17, 2016 | 7 | 2016 |
| Changes in catastrophic health expenditures depending on health policies in Turkey G Kockaya, G Oguzhan, Z Çalşkan Frontiers in Public Health 8, 614449, 2021 | 6 | 2021 |
| Economic impact of clinical research to research centers and opportunity cost for the reimbursement system in Turkey G Koçkaya, M Demir, PD Kockaya, M Tatar, AY Üresin Health 7 (9), 1124-1133, 2015 | 6 | 2015 |
| Treatment cost of metastatic colon cancer in Turkey G Kockaya, M Polat, A Wertheimer, A Ozet, S Malhan, İM Vural, A Akbulat, ... Farmeconomia. Health economics and therapeutic pathways 14 (1), 19-25, 2013 | 6 | 2013 |
| Tıbbi cihazlarda sağlık teknolojisi değerlendirmesi G Koçkaya, M Tatar Sağlık Ekonomisi ve Politikası Derneği, 2013 | 6 | 2013 |
Kagan AtikelerUtrecht Universityuu.nl üzerinde doğrulanmış e-posta adresine sahip
